| Literature DB >> 34396072 |
Hilal Yeşil1, Sibel Eyigör2, Menekşe İnbat2, Ferah Bulut1.
Abstract
OBJECTIVES: This study aims to investigate the effect of complex decongestive therapy (CDT) on the kinesthetic sense of hands, upper extremity function, and the quality of life in patients with breast cancer-related lymphedema (BCRL). PATIENTS AND METHODS: Between August 2018 and August 2019, total of 50 women with BCRL (mean age: 56.5±9.6 years; range, 36 to 71 years) were included in the study. Kinesthetic sense of the hand, upper extremity function (Disabilities of the Arm, Shoulder and Hand [DASH]), quality of life (European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire [EORTC QLQ-C30]), and arm volume of all patients were evaluated before and after the treatment. All patients received CDT for 20 sessions for 1 h over a total of four weeks.Entities:
Keywords: Complex decongestive therapy; disabilities of the arm; kinesthetic sense; lymphedema; quality of life; shoulder and hand
Year: 2021 PMID: 34396072 PMCID: PMC8343150 DOI: 10.5606/tftrd.2021.5191
Source DB: PubMed Journal: Turk J Phys Med Rehabil ISSN: 2587-1250
Demographic and clinical characteristics of patients (n=50)
| n | % | Mean±SD | |
| Age (year) | 56.5±9.6 | ||
| Education level | |||
| Illiterate | 3 | 6 | |
| Elementary school | 17 | 34 | |
| Middle or high school | 21 | 42 | |
| University | 9 | 18 | |
| Operation type | |||
| Total mastectomy | 23 | 46 | |
| Partial mastectomy | 13 | 26 | |
| Modified radical mastectomy | 14 | 28 | |
| Postoperative duration (month) | 67.5±54.6 | ||
| Duration of lymphedema (month) | 21.2±10.7 | ||
| Chemotherapy (yes) | 49 | 98 | |
| Number of chemotherapy cures | 7.9±3.1 | ||
| Radiotherapy (yes) | 40 | 80 | |
| Number of radiotherapy sessions | 23.0±12.3 | ||
| Cigarette (yes) | 4 | 8 | |
| Body mass index (kg/cm2) | 31.2±5.0 | ||
| SD: Standard deviation. | |||
Change in volume of involved limbs, and EORTC-QLQ-C30 and DASH scores after treatment
| Variables | Before treatment | After treatment | |
| Affected extremity volume (mL) | 3920.1±897.9 | 3297.6±773.1 | <0.001 |
| EORTC-Q30-functional | 72.4±18.6 | 77.4±13.7 | 0.012 |
| EORTC-Q30-symptom | 26.5±12.7 | 20.9±11.3 | <0.001 |
| EORTC-Q30-global health | 58.0±18.3 | 70.7±17.9 | <0.001 |
| DASH | 48.5±30.5 | 39.9±21.9 | 0.016 |
| Jamar | 14.2±6.6 | 14.1±4.7 | 0.897 |
| EORTC-QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire; DASH: Disabilities of the Arm, Shoulder and Hand; SD: Standard deviation. | |||
Change in kinesthetic sense score, and kinesthetic sense loss ratio after treatment
| Before treatment | After treatment | ||||
| % | Mean±SD | % | Mean±SD | ||
| Kinesthetic sense score of the hand | |||||
| Visual | 2.7±0.4 | 2.9±0.3 | 0.008 | ||
| Kinesthetic | 2.4±0.5 | 2.7±0.4 | <0.001 | ||
| Kinesthetic sense lost | |||||
| Visual | 42.5 | 30 | 0.035 | ||
| Kinesthetic | 80 | 55 | 0.001 | ||
| SD: Standard deviation. | |||||